JP2016539138A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539138A5
JP2016539138A5 JP2016536145A JP2016536145A JP2016539138A5 JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5 JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5
Authority
JP
Japan
Prior art keywords
optionally substituted
benzo
cyclohepta
pyridazin
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539138A (ja
JP6992960B2 (ja
Filing date
Publication date
Priority claimed from GB201321227A external-priority patent/GB201321227D0/en
Priority claimed from GB201323021A external-priority patent/GB201323021D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053548 external-priority patent/WO2015082887A2/en
Publication of JP2016539138A publication Critical patent/JP2016539138A/ja
Publication of JP2016539138A5 publication Critical patent/JP2016539138A5/ja
Application granted granted Critical
Publication of JP6992960B2 publication Critical patent/JP6992960B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536145A 2013-12-02 2014-11-28 キナーゼ阻害剤の用途 Expired - Fee Related JP6992960B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1321227.9 2013-12-02
GB201321227A GB201321227D0 (en) 2013-12-02 2013-12-02 Use of kinase inhibitors
GB201323021A GB201323021D0 (en) 2013-12-24 2013-12-24 Use of kinase inhibitors
GB1323021.4 2013-12-24
PCT/GB2014/053548 WO2015082887A2 (en) 2013-12-02 2014-11-28 Use of kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080908A Division JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Publications (3)

Publication Number Publication Date
JP2016539138A JP2016539138A (ja) 2016-12-15
JP2016539138A5 true JP2016539138A5 (enExample) 2017-12-28
JP6992960B2 JP6992960B2 (ja) 2022-02-03

Family

ID=52016110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536145A Expired - Fee Related JP6992960B2 (ja) 2013-12-02 2014-11-28 キナーゼ阻害剤の用途
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Country Status (4)

Country Link
US (1) US9801880B2 (enExample)
EP (1) EP3076966A2 (enExample)
JP (2) JP6992960B2 (enExample)
WO (1) WO2015082887A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN115504967A (zh) * 2021-06-23 2022-12-23 南京正大天晴制药有限公司 作为axl抑制剂的1,2,4-三唑化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223172A1 (en) * 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
RS53281B (sr) * 2006-12-29 2014-08-29 Rigel Pharmaceuticals Inc. Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
KR100900289B1 (ko) 2007-06-21 2009-05-29 엘지전자 주식회사 직교 주파수 분할 다중화 시스템에서 제어 채널을 송수신하는 방법
AU2008317404B2 (en) 2007-10-19 2014-12-18 Cell Signaling Technology, Inc. Cancer classification and methods of use
EP2379559B1 (en) * 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8603740B2 (en) * 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
TWI557121B (zh) * 2011-04-21 2016-11-11 原真股份有限公司 新穎激酶抑制劑

Similar Documents

Publication Publication Date Title
JP2020105211A5 (enExample)
JP5529004B2 (ja) Ｈｓｐ９０阻害剤として有用なトリアジノンおよびジアジノン誘導体
US20260085058A1 (en) Degraders of son of sevenless homolog 1
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
TWI641371B (zh) 免疫相關及發炎疾病之治療
CN105492439B (zh) 作为溴结构域抑制剂的取代的双环化合物
AU2014272776C1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ES2484042T3 (es) Compuestos de triazol que modulan la actividad de HSP90
JP2012515225A5 (enExample)
AU2018335617B2 (en) Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202545942A (zh) Ｃｄｋ抑制劑
JP2016517857A5 (enExample)
JP2020128402A (ja) キナーゼ阻害剤の用途
EP2861579A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP2017511360A5 (enExample)
JP2023507634A5 (enExample)
JP2016525104A5 (enExample)
AU2020382002B2 (en) ERAP1 modulators
Mounika et al. An overview of CDK enzyme inhibitors in cancer therapy
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
JP2015515477A (ja) Ｈｓｐ９０活性を調節する新規トリアゾール化合物
US20220347176A1 (en) Phenyl-sulfamoyl.benzoyc acids as erap1 modulators
JP2011518168A5 (enExample)
AR044648A1 (es) Combinaciones terapeuticas
EP3624805A1 (en) Pyrazoloquinazolinone antitumor agents